Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

13.48

Mkt cap

1.3B

Volume

555K

High

13.68

P/E Ratio

-26.82

52-wk high

18.51

Low

13.15

Div yield

N/A

52-wk low

6.13

ARS Pharmaceuticals has announced that its product, neffy® (Epinephrine Nasal Spray), is now available on Express Scripts Commercial National Formularies as of November 22, 2024. This inclusion expands access for patients and caregivers managing Type 1 Allergic Reactions.

Portfolio Pulse from

December 19, 2024 | 10:45 pm

ARS Pharmaceuticals has announced that its licensing partners have filed for approval of neffy, an epinephrine nasal spray, in China, Japan, and Australia. This marks a significant step in expanding the product's availability in the Asia Pacific region.

Portfolio Pulse from

December 12, 2024 | 7:45 pm

ARS Pharmaceuticals is launching the neffyinSchools program to provide free needle-free epinephrine nasal spray to eligible K-12 schools in the U.S. This initiative aims to enhance emergency treatment for allergic reactions, including anaphylaxis.

Portfolio Pulse from

December 04, 2024 | 1:15 pm

ARS Pharmaceuticals, Inc. (SPRY) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included company executives and analysts from major financial firms.

Portfolio Pulse from

November 13, 2024 | 6:00 pm

ARS Pharmaceuticals, Inc. (SPRY) reported a Q3 loss of $0.20 per share, missing the Zacks Consensus Estimate of a $0.18 loss. This is a larger loss compared to $0.16 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

ARS Pharmaceuticals has launched neffy, an epinephrine nasal spray, in the US and received priority review for a supplemental NDA. They have an exclusive license agreement with ALK-Abelló for commercialization in Europe and Canada, with a potential deal value of $465 million. The company is well-capitalized with $349.6 million in cash.

Portfolio Pulse from

November 13, 2024 | 11:45 am

Wall Street analysts have set an average price target for ARS Pharmaceuticals, Inc. (SPRY) that suggests a potential upside of 67.6%. This optimistic outlook is supported by positive trends in earnings estimate revisions.

Portfolio Pulse from

November 06, 2024 | 4:00 pm

ARS Pharmaceuticals is presenting seven abstracts on intranasal epinephrine at the 2024 ACAAI Annual Scientific Meeting, covering topics like cardiovascular safety and real-world data in pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:37 pm

ARS Pharmaceuticals (NASDAQ:SPRY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $26.43. The company has shown significant revenue growth but struggles with profitability.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.